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Abstract
The New Delhi Metallo-b-lactamase (NDM-1) gene makes multiple pathogenic microorganisms resistant to all known b-
lactam antibiotics. The rapid emergence of NDM-1 has been linked to mobile plasmids that move between different strains
resulting in world-wide dissemination. Biochemical studies revealed that NDM-1 is capable of efficiently hydrolyzing a wide
range of b-lactams, including many carbapenems considered as ‘‘last resort’’ antibiotics. The crystal structures of metal-free
apo- and monozinc forms of NDM-1 presented here revealed an enlarged and flexible active site of class B1 metallo-b-
lactamase. This site is capable of accommodating many b-lactam substrates by having many of the catalytic residues on
flexible loops, which explains the observed extended spectrum activity of this zinc dependent b-lactamase. Indeed, five
loops contribute ‘‘keg’’ residues in the active site including side chains involved in metal binding. Loop 1 in particular, shows
conformational flexibility, apparently related to the acceptance and positioning of substrates for cleavage by a zinc-
activated water molecule.
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Introduction
The imminent threat posed by the recent discovery and
dissemination of the plasmid encoded New Delhi Metallo-b-
lactamase (NDM-1) gene (blaNDM-1) harbored by multiple
pathogenic microorganisms has prompted the formation of a global
scientific corps d’arme´e [1]. Biochemical and structural elucidation of
NDM-1 facilitates the thorough mechanistic understanding re-
quired for a rational design of small molecule inhibitors specific to
NDM-1 for co-administration with b-lactam antibiotics. The crystal
structures of NDM-1 presented here reveal an open, enlarged and
flexible active site that explains the observed extended spectrum
activity of this zinc dependent b-lactamase.
One of the last lines of defense against multiple and extensively
drug resistant infections is the carbapenem class of b-lactam
antibiotics, which was developed to evade b-lactamase mediated
resistance posed by aerobic as well as anaerobic pathogens.
Unfortunately, the integrity of the ‘‘big guns’’ (meropenem,
imipenem, doripenem, ertapenem) has become compromised by a
number of b-lactamases with extended spectrum activity, that is, the
ability to inactivate all classes of b-lactam antibiotics, including
carbapenems [2].
b-Lactams are the most broadly used antibacterials world-wide
due to their effectiveness at irreversibly inhibiting cell wall
biosynthetic enzymes required for peptidoglycan recycling, and
minimal toxicity in humans [3,4]. The first b-lactam discovered—
penicillin—inhibits the function of the D-Ala-D-Ala transpeptidase
that links the peptidoglycan molecules in bacteria [4]. Simulta-
neously, cell wall hydrolases and autolysins continue to break
down peptidoglycan crosslinks, resulting in cellular lysis and death.
Since the discovery of penicillin, several classes of naturally
occurring and semi-synthetic b-lactams have entered the clinic.
Concomitantly, broad use of b-lactams as antibacterials applies a
selective pressure that increases the reproductive success of
pathogenic strains carrying evolved b-lactamase genes capable of
combating our arsenal of b-lactam antibiotics.
The vast structural diversity designed into the semi-synthetic b-
lactams evades b-lactamase mediated resistance by either
preventing initial Michaelis complex formation, or by stabilizing
transient intermediates that inhibit further b-lactam turnover.
Carbapenems have proven to be the most effective broad-
spectrum b-lactams, and their utility is generally reserved as a
last line of defense against the toughest drug-resistant infections
including MRSA [5], XDR-TB [6], and bacterial meningitis [7].
However, it appears that the ‘‘target’’ met the challenge. In the
past several years, new pathogenic strains carrying carbapenemase
genes have been documented in patients from India, Pakistan,
Bangladesh and other countries [8,9,10,11,12,13,14]. Carbapene-
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mases are members of class A (KPC, IMI/NMC, SME), class B
(IMP, VIM, SPM) and D (OXA) b-lactamases, for review see
references [15,16,17]. Class B b-lactamases depend on divalent
cation metal cofactors for their activity, and are described as
metallo-b-lactamases (MBLs) [15,17,18,19]. Unlike serine b-
lactamases, MBLs are not inhibited by the classic irreversible b-
lactamase inhibitors such as clavulanic acid, sulbactam and
tazobactam, but instead are inhibited by metal chelators such as
EDTA and o-phenanthroline [15,16,19]. Thiol compounds such
as 2-omega-phenylalkyl-3-mercaptopropionic acid [20] and N-(2-
mercaptoethyl)-2-phenylacetamide [21] are also competitive
inhibitors. However, thus far the therapeutic potential of these
inhibitors has not been demonstrated.
MBLs have been found in widely distributed bacteria such as
Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii
[14,15,22,23]. VIM and IMP are the most frequently acquired
subclasses of B enzymes [16]. MBLs show significant diversity of
the active site, catalytic properties, and metal ion requirements
and have been divided into three subclasses: B1, B2, and B3
[2,15,16]. Subclass B1 includes several chromosomally encoded
enzymes BcII, Bacillus cereus [24], CcrA, Bacteroides fragilis [25],
BlaB, Chryseobacterium meningosepticum [26], and transferable VIM,
IMP, SPM, and GIM type enzymes [15,27,28]. Subclass B2
includes CphA [29] and ImiS [30] lactamases from the Aeromonas
species and Sfh-I from Serratia fonticola [31]. Subclass B3 is
represented by L1 from Stenotrophomonas maltophilia [32,33], FEZ-1
from Fluoribacter gormanii [34,35], GOB from E. meningoseptica
[36,37], CAU-1 from Caulobacter crescentus [38,39], and THIN-B
from Janthinobacterium lividum [40].
A new mobile subgroup B of MBLs was recently discovered and
named New Delhi Metallo-b-lactamase (blaNDM-1). This multi-
drug resistance gene was characterized initially in an isolate from
Sweden that originated from New Delhi, India. Since then,
Enterobacteriaceae isolates harboring the NDM-1 gene have been
found in multiple areas of India, Pakistan, Bangladesh but also in
the USA, Canada, China, Japan, and United Kingdom
[8,9,10,11,12,13,14]. The emergence of blaNDM-1 in India and
China has been linked to its spread on the IncL/M incompatibility
plasmid group types [41]. A current survey of the New Delhi
vicinity identified NDM-1 carrying isolates from drinking water
and seepage [22]. NDM-1 has been reported to be a highly potent
carbapenem-hydrolyzing, zinc-dependent MBL. When expressed
in bacteria, it makes these bacteria resistant to a broad range of b-
lactams. Currently, no inhibitor of NDM-1 approved for medical
treatment is available. NDM-1 positive bacterial infections can
only be treated with a few antibacterials, including colistin,
tigecycline, fluoroquinolones, D-captopril, and polymyxin B [42].
In view of the emerging multidrug-resistant strains carrying NDM-
1, the discovery of effective inhibitors is critical and urgent. Here
we report hydrolytic activity of NDM-1 against selected b-lactams
and carbapenems, the three high-resolution crystal structures of
apo- and the first structure of monometalated form of NDM-1
derived from K. pneumoniae. Our results show that NDM-1 is
unique among other MBLs due to its enlarged and flexible active
site, and explain the observed extended spectrum b-lactamase
activity.
Results and Discussion
Expression, purification and structure determination of
NDM-1
The NCBI database lists a number of identical sequences to
NDM-1 from K. pneumoniae [CAZ39946)] from a number of other
organisms [BAJ76899 [Stenotrophomonas maltophilia], ADY00041
and ADP20459 [E. coli], AEA41876 [Acinetobacter baumannii],
ADU02194 [A. junii], and ADP37377 [Enterococcus faecium]].
Identical sequence entries are found in other records where the
N-terminal region is missing. The N-terminal region of the NDM-
1 protein contains a signal peptide [1–28] according to the
Phobius transmembrane topology and signal peptide prediction
server [43] consistent with the possible cleavage site after residue
28. Several other MBLs (VIM-1-Ec, VIM-2-Pa, IMP-1-Ab and
IMP-4-Kp) contain signal peptides. In contrast, the PSORTb
subcellular localization tool predicts no signal peptide and no
predictive localization of the enzyme [44]. The sequence
alignment of several selected MBLs reinforces the presence of a
signal peptide (Fig. S1)with possible localization to the periplasm.
We expressed in E. coli full-length recombinant K. pneumoniae
NDM-1 b-lactamase, but because it expressed poorly and showed
low solubility, we designed several constructs. These constructs
were based on the NDM-1 homology models obtained using tools
developed as part of the Protein Structure Initiative [45] and low
sequence similarity MBLs with structures available in Protein Data
Bank (PDB) IMP-1, PDB id 1DD6 [46], VIM-2, PDB id 2YZ3
[47] and VIM-4, PDB id 2WHG [48]. Three recombinant NDM-
1 b-lactamases: full-length NDM-1, and two constructs NDM-1
D38 and NDM-1 D36NY, which showed improved solubility,
were expressed and purified to homogeneity. Purified enzymes
exhibited a single band on SDS-PAGE, indicating Mr = 28.5 and
24.5 and 24.8 kDa for NDM-1, NDM-1 D38, and NDM-1
D36NY, respectively.
NDM-1 Structure
The three apoNDM-1 structures include two pairs of monomers
A and B and one monomer A, and the structure of monometalated
NDM-1 (mZnNDM-1 D36NY) includes four monomers (A, B, C,
D), respectively in the asymmetric unit, providing nine crystallo-
graphically independent views of the molecule for NDM-1 D38,
NDM-1 D36NY (monoclinic), NDM-1 D36NY (orthorhombic),
mZn-NDM-1 D36NY (tetragonal) (Table 1). Full length NDM-1
and NDM-1 D36NY are monomers in solution as shown by size
exclusion chromatography (Fig. S2). The model for NDM-1 D38
contains 226 residues (45–270) out of a possible 232 residues and
131 water molecules. The electron density maps obtained for the
NDM-1 D38 structure allowed modeling of 226 residues of both A
and B chains, except the 10 N-terminal residues including the
three residues Ser-Asn-Ala left over from cloning, which are
disordered and not included in the final model. The NDM-1 D38
models were refined against 2.0 A˚ data with a final Rwork of 19.5%
and Rfree of 24.3% (Table 1). The structure of NDM-1 D36NY,
which includes two chains each containing residues of 45–270 (A)
and 44–270 (B), is very similar to that of NDM-1 D38 (rms
difference between Ca atoms of comparing 452 residues of both
chains is 0.21 A˚), except for a few loop regions and an acetate
molecule found in the active site in chain A. The two structures of
NDM-1 D36NY obtained under different crystallization condi-
tions and in different crystal packing are virtually identical (rmsd
between Ca atoms of comparing 436 residues of both chains is
0.45 A˚). Our NDM-1 D38 and two NDM-1 D36NY structures are
also very similar to the recently published high-resolution structure
of dizinc NDM-1 D29 [49], except for the N-terminal region
(missing or disordered in our structures and some loop regions (see
below)). The structure of mZnNDM-1 D36NY was obtained in the
presence of 10 mM zinc chloride. The structure contains one zinc
atom bound in the active site to the metal site 1 (Zn1) (see below).
The metal bound structure is very similar to apo structures (for
example, rmsd between Ca atoms of apoNDM-1 D38 comparing
218 residues of chain B of mZnNDM-1 D36NY is 0.46 A˚).
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NDM-1 resembles the common b-lactamase fold, although it
shows low sequence similarity to b-lactamases deposited in PDB
(20–33% sequence identity). The protein is made up of four layers
a/b/b/a and forms a sandwich. The core of NDM-1 consists of
two b-sheets, one (N-terminal) is composed of seven antiparallel
strands (b1–b7) and the other (C-terminal) is composed of five
antiparallel strands (b8–b12). The N-terminal b-sheet is highly
twisted (.100 degrees). The interaction between b-sheets is mainly
hydrophobic. The seven connecting helices are located below (a1–
a4 and 310 helix 5) and above (a6–a7) the plane of the b-sandwich
(Fig. 1A). The interactions between helices and b-sheets are
hydrophobic but also involve several hydrogen bonds (Q96 with
carbonyl of Y64, T98 with carbonyl of A92, Y229 with carbonyl of
Leu209 and S232 with carbonyl of P187). Strands and helices are
connected through flexible loops with the most prominent loop
(residues 206–228) located above an ,600 A˚3 (see discussion)
active site cavity containing a sulfate ion in monomer A and two
sulfate ions in monomer B. The two b-sheets and four associated
helices show a previously reported two-fold symmetry of the
‘‘bbbbabab’’ topological motif [24]. The symmetry is not ideal
with one unit showing a ‘‘bbbabab’’ motif and the second unit
‘‘bbbbababab’’ is enlarged. The NDM-1 secondary structure is
shown in Fig. 1A.
The search for structural homologs of NDM-1 using the DALI
server [50] identified a number of closely related homologs. More
than 400 entries were identified with a Z-score higher than 4. The
closest structural homologs are MBLs (class B), followed by class A,
C, and D b-lactamases. Over 1,200 b-lactamase superfamily
members were also identified in 340 species showing highly diverse
sequences. The top 250 structural homologs (Z-score.10) were
clustered using CD-HIT [51] with a 90% sequence identity cut-off
value resulting in 40 structure classes. Similar clustering was
observed using 80% and 70% cut-off values. Representative
structures from the 40 structure clusters were aligned based on the
secondary structure (Fig. S3). The alignment reveals that the
NDM-1 structure (and its MBL homologs) displays expansions in
Table 1. Summary of the NDM-1 crystallographic data.
Data collection statistics
NDM-1 D38
(39–270)
NDM-1 D36NY
(37–270)
NDM-1 D36NY
(37–270)
mZnNDM-1 D36NY
(37–270)
Space group P21 P21 I222 P43212
Unit cell (A˚) a = 59.71
b = 51.11
c = 70.68
b= 106.96
a = 59.76
b = 50.86
c = 70.72
b= 106.98
a = 66.05
b = 83.27
c = 10.5.4
a = 97.94
b = 97.94
c = 187.55
Wavelength (A˚) 0.9793 0.9793 0.9792 1.2825
Highest Resolution bin (A˚) 2.03-2.00 2.39-2.35 2.34-2.30 2.31-2.27
Number of observed reflections 26835 (1377)b 16892 (709)b 12326(528)b 42642 (2066)b
Rmerge (%)
a 15.3 (55.7)b 14.4 (44.8)b 9.1(33.4)b 10.4 (57.0)b
Completeness (%) 95.0 (96.8)b 97.6 (80.9)b 95.5(84.3)b 99.1 (98.1)b
I/s I 6.3 (2.5)b 5.9 (2.1)b 11.9(3.5)b 6.3 (2.0)b
Phasing and Refinement MR MR MR MR
Search model Chain A of 2YZ3 Chain A of 3RKJ Chain A of 3RKJ Chain A of 3Q6X
Phasing resolution range (A˚) 38.4-2.00 40.7-2.35 36.9-2.31 38.4-2.27
Refinement resolution range (A˚) 38.4-2.00 40.7-2.35 36.9-2.31 38.4-2.27
Rcryst (%) 19.2 20.8 20.3 18.3
Rfree (%) 24.3 28.3 26.0 23.6
Number of protein residues 464 464 237 928
Solvent molecules 262 170 61 324
Bond lengths (A˚) 0.007 0.017 0.012 0.011
Bond angles (deg) 1.19 1.61 1.52 1.33
B-factors (A˚2) 30.1 30.6 50.6 32.6
Protein main chain 25.83 28.62 46.60 30.08
Protein side chain 31.04 30.31 52.92 33.51
Solvent (Water) 38.49 34.58 47.28 37.46
Wilson B-factor (A˚2) 25.89 24.97 36.45 30.32
Ramachandran Plot (%)c
Preferred 97.4 98.0 97.8 99.5
Generously allowed 2.6 2.0 2.2 0.4
Disallowed 0 0 0 0.1
PDB ID 3RKJ 3RKK 3SBL 3SFP
aRmerge =ShklSijIi{vIwj=ShklSijvIwj, where Ii is the intensity for the ith measurement of an equivalent reflection with indices h, k, and l.
bNumbers in parentheses are values for the highest-resolution bin.
cRefined using PHENIX.
doi:10.1371/journal.pone.0024621.t001
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some loop regions, for example ASL1, ASL4 (Fig. S4, see below).
The proteins belonging to the 40 structure clusters show several
different catalytic activities (lactamase, oxidoreductase, hydroxya-
cylglutathione hydrolase, glyoxalase, nitric oxide reductase,
parathion hydrolase, teichoic acid phosphorylcholine esterase).
These enzymes utilize a broad range of substrates (b-lactams,
hydroxyacylglutathione, nitric oxide, parathion, phosphorylcho-
line) suggesting that the lactamase fold seems highly adaptable and
has evolved to support multiple functions and accept a wide range
of substrates [15].
Active site expansion in NDM-1 and implications for
ligand binding
Active site template searches using ProFunc [52] identified the
B. fragilis MBL (PDB id 1BMI) [53] as an active site match with a
similarity score of 422.6 and E-value of 1.09610‘210. Seven active
site residues in the B. fragilis MBL structure (His82, His84, Asp86,
His145, Cys164, Asn176, His206) matched the corresponding
residues in NDM-1 (His120, His122, Asp124, His189, Cys208,
Asn220, His250) with an rmsd of 1.87 A˚ (over 13 atoms). Overall,
the template identified 19 identical residues and 8 similar residues
in the NDM-1/B. fragilis MBL active sites with local sequence
identity of 52.8%. These residues form a solvent accessible surface
that extends along the middle of the molecule between two b-
sheets (Figs. 1, 2, S5). This well-defined hydrophobic and partly
positively charged cavity is shaped by five active site loops (ASL1–
5). From the bottom (as viewed in Figs. 1A, 2 and 3), two loops
between strands b2 and b3 (residues 65–73, ASL1) and b5 and a2
(residues 118–124, ASL2) are contributing to form the base of the
active site. At the top of the pocket, loops between b8 and b9
(residues 184–194, ASL3), b10 and a5 (residues 206–228, ASL4),
and b11 and b12 (residues 248–255, ASL5) form the roof and
walls of the active site (Fig. 1). In MBLs, these loops provide key
conserved side chains for coordinating metal ions as well as
proposed catalytic general acid/base. As evident from the NDM-1
structures, these residues appear to have well-defined conforma-
tions in the absence and presence of metal ions and this part of the
active site is structurally well conserved (Fig. 2) (see below).
Additional residues from these loops, in particular ASL1, seem to
also participate in the positioning of ligands in the active site in an
orientation suitable for hydrolysis of the b-lactam ring. This is
evident from several crystal structures of MBLs obtained with
ligands [26,34,46,54,55,56]. MBLs, including NDM-1, show the
longest ASL1 as compared with other b-lactamase superfamily
members (Fig. S3). The alignment of the NDM-1 structure with
the closest MBL structural homologs, di-zinc VIM-4 (PDB id
2WHG, Z-score 31.9, rmsd 1.9 A˚), VIM-2 (PDB id 2YZ3, Z-score
11.2, rmsd 1.45 A˚, between chain A of 3RKJ and chain A of
2YZ3), and IMP-1 (PDB id 1DD6, Z-score 11.7, rmsd 1.52 A˚,
between chain A of 3RKJ and chain A of 1DD6) reveals several
unique features of the NDM-1 structure (Fig. 1). Region 162–176
shows a very different conformation with a short 310 helix (a4)
formed in the middle of the loop region (Fig. 1B). This region
forms a b-strand in VIM-2, VIM-4 and IMP-1. NDM-1 and IMP-
1 show the longest ASL1 loop (Figs. 1 and S1) but NDM-1 has a
Phe insertion instead of Trp in this loop (Fig. S1). This smaller side
chain may provide more flexibility to accommodate bulky
substrates. In NDM-1, ASL4 shows a more open conformation
and the C-terminal helix is quite shifted in comparison to VIM-2,
VIN-4 and IMP-1. However, the most important difference
between these MBLs structures is a significantly larger active site
cavity. This region in NDM-1 provides the opportunity to
accommodate large substrates. In VIM-2, VIM-4 and IMP-1,
side chains from the ASL1 and ASL4 loops bridge over the active
site, dividing it into sub-cavities [46,47,48,53]. In contrast, the
NDM-1 ASL1 and ASL4 loops are shifted outward considerably
(Figs. 1B and 3) and do not close over the active site but instead
leave the site much more open and accessible to potential ligands
(Figs. 1B and 3).
There is a reduction in the volume of residues contributing to
the active site (Ala121 in NDM-1, typically Phe or Trp in other
MBLs; Tyr229 in NDM-1, typically Trp in other MBLs; sequence
Figure 1. NDM-1 structure and comparisons with selected carbapenemases. A. Aerial view of active site (represented by two phosphate
ions), the protein is made up of four layers, a/b/b/a, and forms a sandwich. Secondary structure elements and N- and C-termini are labeled. B.
Comparison of K. pneumoniae NDM-1 (PDB id 3RKJ – magenta, N and C-termini are labeled) with three MBLs with carbapenemase activity P.
aeruginosa VIM-2 (PDB id 2YZ3 - wheat), P. aeruginosa IMP-1 (PDB id 1DD6 - light blue) and P. aeruginosa VIM-4 (PDB id 2WHG - pale green). Loops
contributing to the active site are labeled ASL1–5. Zn1 and Zn2 (blue spheres) are from the structure of VIM-2.
doi:10.1371/journal.pone.0024621.g001
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Ala72Val73 in NDM-1 in ASL1, which is typically Val or Phe in
other MBLs; Phe70 in NDM-1 in ASL1 which is Trp in IMP-1
and related MBLs). There is also a reduction in the volume of
residues contributing to the hydrophobic core. One indication of
this volume reduction is an increase (15.2%) in alanine occurrence
in NDM-1, which is nearly double the average alanine occurrence
typically found in other proteins. These changes can contribute to
the opening of the groove to solvent and can also increase the
flexibility of structural elements. A larger active site would be more
accessible to a broader range of antibiotics (or inhibitors) and thus
provide an evolutionary advantage to bacteria. This can explain
the observed enzyme promiscuity in accepting and hydrolyzing a
Figure 2. Active site comparisons of K. pneumoniae apoNDM-1 (PDB id 3RKJ) (aqua) vs monozinc NDM-1 (PDB id 3SFP) (violet) vs di-
zinc NDM-1 PDB id 3Q6X [49] (wheat). Zn19 and Zn29 (wheat) are from the structure of di-zinc NDM-1 and Zn10 is from the structure of monozinc
NDM-1. Conformations of residues coordinating Zn1 (His120, His122 and His189) and Zn2 (Asp124, Cys208 and His250) are shown for all three
structures.
doi:10.1371/journal.pone.0024621.g002
Figure 3. Flexibility of the active site loops. A. Structures of six NDM-1 molecules (identified using PDB ids) were aligned (PDB id 3RKJ (this
work) molecule A - blue, PDB id 3RKJ (this work) molecule B - light blue, PDB id 3SBL (this work) molecule A - green, PDB id 3RKK (this work) molecule
B – red, PDB id 3SFP (this work) molecule B – violet and PDB id 3Q6X [49] molecule B – wheat), hAmp is a hydrolyzed ampicillin and Zn19 and Zn29 are
zinc atoms from the structure of NDM-1 (PDB id 3Q6X molecule B) and Zn10 is from the structure of monozinc NDM-1. B. The structural variability at
each residue position in the ASL1 loop is evaluated across six structurally unique loops shown in A. After a structural alignment of the entire
molecules, the Euclidean distance between the residues’ center-of-mass was measured between all pair combinations at each position. The results
are summarized as a boxplot showing the median, quartiles, maximum and minimum distances for each residue. The aligned loops are shown in
cartoon putty representation, with the loop radius proportional to residue B-factors (view facing active site, left; top-down view, right).
doi:10.1371/journal.pone.0024621.g003
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broad range of b-lactams and carbapenems (Fig. S5). A more open
active site would allow for many substrates to bind in an extended
conformation along the elongated-shaped groove with the b-
lactam ring positioned over the active site metal ions while the rest
of the substrate could be further stabilized by the interaction with
side chains projecting from flexible loops ASL3, ASL4, and ASL5
(Figs. 3, 4 and S5).
To investigate the structural implications of residue substitutions
near the active site cavity, we performed a surface analysis on
IMP-1 (PDB id 1DD6), VIM-2 (PDB id 2YZ3), VIM-4 (PDB id
2WHG), and NDM-1. For each protein, solvent accessible cavities
were identified [57]. NDM-1 has the largest cavity (surface
area = 412.4 A˚2; volume = 591.3 A˚3) followed by IMP-1 (surface
area = 339.5 A˚2; volume = 303.1 A˚3), VIM-2 (surface area =
223.9 A˚2; volume = 140.1 A˚3), and VIM-4 (surface area =
112.4 A˚2; volume = 45.3 A˚3). The active site cavity for each
protein is shown in Fig. 4 (green). It should be noted that the VIM-
2 structure has a bound ligand in the cavity, which may affect the
apo cavity structure and volume. However, even in a bound state
the volume is considerably less than the NDM-1 cavity. To
highlight the differences between the cavities, the molecules were
superimposed onto the NDM-1 molecule. It is evident that the
expanded cavity volume in NDM-1 is due to residue substitutions
occurring in the surrounding loops. Fig. 4 shows the protruding
residues in both stick and surface rendered forms.
In our three apo and one monozinc structures, there are nine
independent representations of NDM-1 molecules with different
crystallization conditions and packing environments. In these
structures, most active site loops show very small conformational
changes with the exception of ASL1 (Figs. 1B and 3) and to some
extent ASL4. These are key loops contributing to the expansion of
active site accessibility. Zhang and Hao, based on the comparison
of their NDM-1 structure with other MBLs, hypothesized that the
ASL1 loop may be flexible [49]. Our data clearly demonstrate that
this is indeed true. As shown in Fig. 3B, ASL1 shows the ability of
assuming several alternative conformations that may be important
for binding ligands.
Metal binding
NDM-1 has both b-lactamase and carbapenemase activities that
are zinc-dependent [22,49,58,59], this work. Three of our
apoNDM-1 structures are zinc-free and are the first structures of
a wild-type apo-enzyme in subclass B1. Interestingly, the second
crystal form (PDB id 3RKK) was obtained in the presence of
5 mM zinc acetate. No zinc is found in the structure and only an
acetate ion can be modeled in the active site interacting with
His250. Because of the location, the architecture and sequence
conservation of the active site in NDM-1 are very similar to the
metal binding sites of other b-lactamases. The active site similarity
(presence of principal zinc-binding motif (HaHqD)) allows us to
unambiguously identify all residues involved in zinc coordination.
The active site template search identified all residues that are
involved in metal binding in other MBLs of B1 subclass. It is
predicted that NDM-1 would bind two zinc ions. Zinc 1 would be
coordinated by His120, His122 and His189 and zinc 2 by Asp124,
Cys208 and His250. Indeed, zinc was found bound to the Zn1 site
in the crystal structure of NDM-1 obtained in the presence of zinc
chloride. All four monomers in the asymmetric unit contain zinc
atoms bound to the Zn1 site (His120, His122 and His189),
therefore confirming NDM-1 as a member of subclass B1 of MBLs
[49,59] and showing that Zn1 is a higher affinity site, as predicted
for other MBLs [60,61]. This zinc atom is shifted approximately
0.8 A˚ as compared with the di-zinc NDM-1 structure and shows
somewhat longer Zn-His distances (Fig. 2) [49]. The zinc
coordinating residues are provided by ASL2, ASL3, ASL4, and
ASL5. ASL2 contributes residues coordinating both zinc ions. In
apoNDM-1 structure conformations of some of these residues are
very similar to zinc-bound states (His120, Asp124, and His250),
while others show somewhat different side chain orientations
(His122, His189, and Cys208) (Fig. 2). Cys208 exists in two
orientations in apo-state, one is similar to the zinc bound state and
the other is rotated about 45 and 90 degrees in chain A and B,
respectively. It has been noticed that MBLs are sensitive to metal
chelators and it was suggested that they could bind zinc with lower
affinity [15,16,29,60,62]. The range of affinities for zinc reported
for MBLs vary from micromolar to millimolar. All these residues
are part of the ‘‘keg’’ structure of the active site.
The NDM-1 active site is located on its surface and is fully
accessible to solvent. In the apoNDM-1 structure, two water
molecules are coordinated by zinc-binding side chains, including
Figure 4. Active site expansion of NDM-1. The active site cavity
comparisons of K. pneumoniae NDM-1 (gray) and three MBLs: IMP-1
(light brown), VIM-2 (orange) and VIM-4 (magenta). Superposition of the
IMP-1, VIM-2 and VIM-4 molecules with NDM-1 reveal highly conserved
structural arrangements. The most prominent variations occur between
the catalytic sites (shown as surface representations), in which the side
chains of IMP-1, VIM-2 and VIM-4 restrict the access to the active site by
decreasing the volume of the cavity. The top row depicts NDM-1 and its
active site surface (green) in secondary structure cartoon (left) and
surface representation (right). The subsequent rows show NDM-1
structural alignments with IMP-1, VIM-2 and VIM-4. Each row highlights
the IMP-1, VIM-2 and VIM-4 molecules’ respective active sites, shown as
colored surfaces. To highlight the greater accessibility to the NDM-1
active site, the aligned NDM-1 molecule is shown in surface
representation (right). The obstructing interactions between ASLs
restricting access to active site in IMP-1, VIM-2 and VIM-4 are observed
as colored protrusions through the NDM-1 molecule and are
highlighted for IMP-1, VIM-2 and VIM-4 with black circles.
doi:10.1371/journal.pone.0024621.g004
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Asp124, His122, and His250. In MBLs, the metal ions may have a
dual role in catalysis. One zinc ion activates a metal-bound water
molecule to perform a nucleophilic attack on the b-lactam
carbonyl. The second zinc ion binds and polarizes this carbonyl
group. A negatively charged carboxyl group of a zinc-bound Asp
residue is involved in the activation of the water molecule. During
the reaction, a tetrahedral intermediate is formed, followed by the
delivery of a proton from a general acid/base residue (possibly Asp
or another water molecule) to the lactam nitrogen and the
cleavage of the lactam bond. All required residues are present in
NDM-1 and therefore this enzyme should follow the general MBL
catalytic mechanism involving a hydrolytic water molecule
activated by a metal ion. In the mZnNDM-1 D36NY structures,
there are several water molecules near the zinc atom. Monomer C
contains tightly coordinated water (H-bond distance 2.8 A˚) that
may correspond to the position of the catalytic water molecule
involved in b-lactam hydrolysis. Conserved Asp223 was proposed
to function as the general acid/base during catalysis suggesting
that conserved Thr190 (or Ser), which is centrally positioned on
the loop overhanging the active site, may play an important role in
substrate recognition and transition-state stabilization [61,63]. It is
easy to envision this loop undergoing movements upon substrate
binding. The structure of zinc-free NDM-1, along with the
previously reported structures, provides important insight into the
conformational changes associated with the metal binding
properties of NDM-1.
Steady State Kinetics
NDM-1 kinetic parameters obtained using NDM-1 D38 are
summarized in Table 2. NDM-1 is an extended spectrum zinc
dependent b-lactamase capable of hydrolyzing nearly all classes of
b-lactams, impairing the ability to treat life-threatening infections
with intravenously and orally available carbapenems.. Carbape-
nem substrates appear to be the most specific class of b-lactams for
NDM-1. However, the specificity constants for cephamycin and
penem substrates deviate by less than an order of magnitude,
indicating that the evolved promiscuity is related to the relaxed the
substrate specificity of NDM-1. The observed lack of well-defined
substrate specificity has previously been observed for the MBL
NDM-1 homolog GIM-1 [28,64].
The carbapenems; imipenem, biapenem and tebipenem have
very similar kinetic constants likely due to their structural
similarity. Tebipenem, although turned over less quickly
(kcat = 0.39 s21), has relatively high specificity, with a nearly two
fold tighter Michaelis complex (KM = 69 mM) relative to other
carbapenems. The majority of the Michaelis constants falls
between 50 mM and 150 mM, and includes penem, carbapenem
and cephamycin classes of b-lactams (Fig. S6A–F).
Substrates that are most efficiently (kcat/KM) turned over in
general have extended hydrophobic characteristics that comple-
ment the linear and hydrophobic nature of the NDM-1 active site
cavity (Fig. S5). The primary hydrophobic arrangement is
contributed by residues Leu65, Met67, Pro68, Val73, Gly69,
Phe70, and Val73 of ASL1, which contour the flexible roof of the
active site (Figs. 3, 4 and S5). In addition, alkyl moieties of Leu209,
Ile210, Lys211, Asp212, Lys214, Ala215, Lys216, and Asn220 side
chains of ASL4 give the distal region and base of the active site a
partially hydrophobic surface area, while simultaneously main-
taining hydrogen bond capability. These residues contribute to the
‘‘keg’’ set of side chains that constitute the active site. The degrees
of freedom of the aforementioned residues serve to increase the
flexibility of the active site, thereby increasing promiscuity, but
may do so at the expense of Michaelis complex formation for most
substrates.
In accordance with previous kinetic characterizations of
metallo-b-lactamases GIM-1 [28,64], IMP-1 [65], VIM-2 [66],
and NDM-1 [42], kinetic constants could not be calculated for the
suicide inhibitor clavulanic acid or the monobactam aztreonam.
Although not yet implemented, this observation signifies the
potential of treating NDM-1 harboring pathogenic bacteria with
aztreonam or other structurally similar monobactams in combi-
nation with a new NDM-1 inhibitor.
Mechanistic and drug discovery implications
It is likely that NDM-1 has evolved to have a more open and
flexible active site, to be able to inactivate the highly decorated b-
lactam antibiotics that have progressed over the years from
relatively simple (penicillin) to larger and more complex
compounds with new added substituents. It has been suggested
that evolution of MBLs has enabled these enzymes to hydrolyze
many compounds that interfere with key bacterial pathways, and is
linked to increased flexibility and improved catalysis [61,63,67].
The X-ray structures of NDM-1 presented herein provide a
structural foundation for the corroboration of the proposed
reaction mechanism of NDM-1 and drug design. It seems that
there are three distinct states of the NDM-1: metal free, singly
metalated and doubly metalated. All these states could be targeted
for structure-based inhibitor design. Analysis of structures and
previously reported kinetic and spectroscopic studies on MBL
enzymes allows us to propose a refined mechanism of catalysis for
this antibiotic resistant lactamase. NDM-1 would bind a zinc atom
to the Zn1 site and a second zinc to the Zn2 site. The binding of
the second zinc could be cooperative as proposed for some MBLs.
Table 2. Steady state kinetic parameters of NDM-1 D38. with a selected set of b-lactam antibiotics (see Materials and Methods for
details and Figure S6).
b-lactam
antibiotic b-lactam Class KM (mM) Error % Error Vmax (mM s
21) Error % Error kcat (s21)
kcat/KM
(s21/mM)
Biapenem carbapenem 130 12 9 2.6E-03 5.8E-05 3 49.8 0.38
Imipenem carbapenem 134 12 9 2.5E-03 7.8E-05 3 64.9 0.48
Tebipenem carbapenem 69 7 10 2.8E-03 4.3E-05 3 39.0 0.57
Nitrocefin cephalosporin 3 0.6 20 5.6E-03 2.2E-05 5 12.5 4.18
Cefoxitin cephamycin 95 20 21 5.8E-03 3.4E-05 7 13.2 0.14
Faropenem penem 99 16 16 4.5E-03 4.2E-05 8 14.7 0.15
doi:10.1371/journal.pone.0024621.t002
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This would organize the residue in the active site for productive
catalysis. The key step in catalysis for NDM-1 is likely recognition
of the ligand by side chains in the cavity adjacent to the Zn1 site.
Only ligands conforming to the NDM-1 site would bind. Next, the
b-lactam ring of the ligand coordinates to Zn1, expanding its
coordination number from four to five and activating it for a
nucleophilic attack. It is clear that the ASL1 plays a key role in
positioning the b-lactam ring over the dimetalated site. Deproto-
nation of the metal-bound water molecule by Asp124 to form a
nucleophilic hydroxide moiety is consistent with the postulated pKa
of the zinc-bound water molecule. Once the zinc-bound hydroxide
is formed, it can attack the activated carbonyl carbon of the
substrate, forming a transition-state complex [61,63,68,69]. In the
dimetalated site, the second metal ion likely coordinates the b-
lactam oxygen in a bridging fashion of the substrate. Asp124 may
provide a proton to the penultimate amino nitrogen, similar to that
observed for DapE [70], returning it to its ionized state thus
facilitating product release. Here again the flexibility of ASL1 is
important to release the product. Once the products are released,
a water molecule bridging the two metal ions is replaced. Recent
mechanistic studies of MBL showed that Zn2 is the only metal ion
capable of stabilizing an anionic intermediate that accumulates
during b-lactam hydrolysis, in which the C–N bond has already
been cleaved. Conserved Asp124 would provide a proton to
complete product release.
Kinetic studies with NDM-1 show that the KM for biapenem
and imipenem were 130 mM and 134 mM, respectively (Table 2,
Fig. S6C,D), which are significantly above the minimum inhibitory
concentrations (MICs) against most pathogenic microorganisms
(,2 mg/mL or 6 mM) including Klebsiella spp. and E. coli, and
Pseudomonas aeruginosa [71,72], each of which has been found to
harbor the NDM-1 gene [73]. Pharmacokinetic analysis demon-
strates that human serum levels of biapenem were maintained at
above the aforementioned MICs in young and elderly adults in a
dose dependent manner [74]. Unlike other carbapenems,
biapenem is stable to human renal dihydropeptidase-1 (DHP-1),
eliminating the need to co-administer the DHP-1 inhibitor
cilistatin [75]. These studies suggest that the orally available
carbapenem, biapenem, could be of potential use to treat patients
with NDM-11 linked bacterial infections because theMICs and
human serum concentrations are far below the KM of biapenem
for NDM-1. Therefore, next generation b-lactams used to fight
NDM-1 linked bacterial infection may be derivatives of carbape-
nems like biapenem. However, given the broad specificity and
likelihood of compensatory mutations, novel metallo-b-lactamase
inhibitors will be required.
Materials and Methods
Protein cloning, expression, and purification
The ORF NDM-1 gene from Klebsiella pneumoniae subsp.
pneumoniae MGH 78578 was synthesized chemically and initially
cloned into vector pUC57. The full length NDM-1 and several N-
terminal deletion constructs were subsequently amplified with
KOD DNA polymerase using conditions and reagents provided by
Novagen, Madison, WI and cloned into the pMCSG7 according
to the ligation-independent procedure [76,77] and transformed
into the E. coli BL21(DE3)-Gold strain (Stratagene), which harbors
an extra plasmid (pMgk) encoding one rare tRNA (corresponding
to rare Arg codons, AGG and AGA). These constructs provided a
system to produce a fusion protein containing an N-terminal His6-
tag followed by a TEV protease cleavage site and a target protein
(pMCSG7). To produce the protein, the bacterial culture was
grown at 37uC, 200 rpm in enriched M9 medium [78] until it
reached OD600 = 1.0. After air-cooling it down at 4uC for 60 min,
NDM-1 expression was induced by 0.5 mM isopropyl-b-D-
thiogalactoside (IPTG). The cells were incubated overnight at
18uC, harvested and resuspended in lysis buffer (500 mM NaCl,
5% (v/v) glycerol, 50 mM HEPES pH 8.0, 20 mM imidazole, and
10 mM b-mercaptoethanol). Cells were disrupted by lysozyme
treatment (1 mg/ml) and sonication, and the insoluble cellular
material was removed by centrifugation. The native NDM-1
protein was purified from other contaminating proteins using Ni-
NTA affinity chromatography and the AKTAxpress system (GE
Health Systems) with the addition of 10 mM b-mercaptoethanol
in all buffers as described previously. This was followed by the
cleavage of the His6-tag using recombinant His6-tagged TEV
protease and an additional step of Ni-NTA affinity chromatogra-
phy was performed to remove the protease, uncut protein, and
affinity tag. The pure protein was concentrated using Centricon
(Millipore, Bedford, MA, USA) in 20 mM HEPES pH 8.0 buffer,
250 mM NaCl, and 2 mM dithiothreitol (DTT). Protein concen-
trations were determined from the absorbance at 280 nm using a
molar absorption coefficient (e280 = 28,500 M
21 cm21) calculated
by using the method developed by Gill and Hippel [79]. The
concentration of NDM-1 D38 and NDM-1 D36NY samples used
for crystallization was ,40 mg/mL. Individual aliquots of purified
NDM-1 D38 and NDM-1 D36NY were stored in 280uC until
needed. The full-length protein expressed rather poorly at
,2 mg/L of culture and it could only be concentrated to
,8 mg/mL. Truncation of the first 38 residues of NDM-1 yielded
a much more stable protein construct (NDM-1 D38) with the
expression yield of soluble protein, ,100 mg/L culture that can
be concentrated up to 150 mg/mL.
Protein crystallization
Native NDM-1 as well as several mutants, including NDM-1
D38 (the first 38 N-terminal residues deleted) and NDM-1 D36NY
(the first 36 N-terminal residues deleted followed by Q36N and
Q37Y mutations), were screened for crystallization conditions with
the help of the Mosquito liquid dispenser (TTP Labtech,
Cambridge, MA, USA) using the sitting-drop vapor-diffusion
technique in 96-well CrystalQuick plates (Greiner Bio-one,
Monroe, NC, USA). For each condition, 0.4 mL of protein
(40 mg/mL) and 0.4 mL of crystallization formulation were mixed;
the mixture was equilibrated against 135 mL of the reservoir in the
well. Some protein was prepared in the presence of 5 mM zinc
acetate or 5 mM zinc acetate and 20 mM citrate. Several
commercially available crystallization screens were used including:
MCSG-1–4 (Microlytic Inc. MA, USA) and Index (Hampton
Research, Aliso Viejo, CA, USA) at 16uC and 4uC. Microcrystals
were obtained under several conditions. Crystals of the zinc-free
form of NDM-1 D38 and NDM-1 D36NY in the presence of
5 mM zinc acetate were grown at 16uC by vapor diffusion in
sitting drops containing 0.4 mL of precipitant solution and 0.4 mL
of 40 mg/mL of NDM-1 D38 or NDM-1 D36NY with 5 mM zinc
acetate. The crystals grew within five days and reached sizes of
approximately 0.100 mm60.020 mm60.010 mm3. The best crys-
tals appeared at 16uC under the condition of 0.17 M ammonium
sulfate, 25.5% (w/v) PEG4000 and 15% glycerol, which
corresponds to condition G6 from the MCSG-3 screen. These
crystals had dimensions of 100625610 microns3 and diffracted to
1.9 A˚ using the 19-ID minibeam [80]. The crystals of NDM-1 D38
belonged to the primitive space group P21 with unit cell
parameters a = 59.71 A˚, b = 51.11 A˚, c = 70.6 A˚ b= 106.96u.
The NDM-1 D36NY crystals were also P21 with a similar unit
cell dimension of a = 59.76 A˚, b = 50.86 A˚, c = 70.72 A˚,
b= 106.98u. The asymmetric unit contains two molecules with a
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Vm value of 2.1 A˚
3/dalton (solvent content 41.5%). Data
collection was carried out on the 19-ID beamline of the Structural
Biology Center at the Advanced Photon Source according to the
procedure described previously [81]. Data for the NDM-1 D38
and the NDM-1 D36NY crystals were collected to 2.0 A˚ and
2.35 A˚ at a wavelength of 0.9792 A˚ from the single crystals using a
,20 micron mini-beam and were processed using HKL3000 [82]
(Table 1). The third crystal was obtained from NDM-1 D36NY co-
crystallizing with 10 mM aztreonam in the condition containing
1.8 M ammonium citrate dibasic, and 0.1 M sodium acetate
trihydrate pH 4.6. The I-centered orthorhombic crystal (I222) of
approximately 0.260.160.07 mm, a broken piece from a big
multiple congregate, diffracted beyond 2.0 A˚, though they are
multiple with cell dimensions of a = 66.05 A˚, b = 83.27 A˚,
c = 105.4 A˚. The data were collected using ,75 micron beam.
Crystals of mZnNDM-1 D36NY were obtained in the presence of
10 mM ZnCl2 in the presence of 0.17 M ammonium sulfate,
25.5% (w/v) PEG 4000, 15% (v/v) glycerol and 20 mM citrate
and belong to tetragonal space group P43212, with unit cell
dimensions of a = 97.94 A˚, b = 97.94 A˚, c = 187.55 A˚. These
crystals diffracted X-rays to 2.2 A˚ (Table 1).
Size exclusion chromatography
The molecular weight of native NDM-1 protein in solution was
determined by size-exclusion chromatography using a Superdex
200 GE Healthcare 16/60 column. The column was calibrated
with aprotinin (6.5 kDa), carbonic anhydrase (29 kDa), conalbu-
min (75 kDa), catalase (232 kDa), and thyroglobulin (669 kDa).
The separation was carried out at 22uC at a flow rate of 2.0 mL/
min. The calibration curve of Kav versus log molecular weight was
prepared using the equation Kav = (Ve2Vo/)/(Vt2Vo,), where
Ve = elution volume for the protein, Vo = column void volume,
and Vt = total bed volume. Size exclusion chromatography
indicates a protein monomer (Fig. S2).
Data collection
An X-ray diffraction data set extending to 2.0 A˚ resolution was
collected at the Structural Biology Center 19-ID beamline with the
20620 mm mini-beam at the Advanced Photon Source, Argonne
National Laboratory using the program SBCcollect. The crystal
was pre-cooled in liquid nitrogen and exposed for 3 sec. per 1.0u
rotation of omega with the crystal to a detector distance of
280 mm at 100 K using 0.9792 A˚ X-rays. The complete data
were recorded on an ADSC 315r CCD detector scanning 185u on
omega until the crystal was severely decayed. The second crystal
form of NDM-1 D36NY was prepared in the presence of 5 mM
zinc acetate and diffracted beyond 2.35 A˚ and a data set was
collected similarly at the same beamline. The third crystal form
produced by co-crystallization with aztreonam diffracted beyond
2.0 A˚, however, the data were good only to 2.30 A˚, because the
crystal was multiple and decaying during the data collection. The
data were collected by the similar procedures. For the mZnNDM-
1 D36NY crystal, the energy was set to 1.2825 A˚ to exploit
anomalous signal from zinc atoms. All of the diffraction data were
integrated and scaled with the HKL3000 suite [82]. The
processing statistics are given in Table 1.
Structure solution and refinement
The structure of NDM-1 D38 was determined by molecular
replacement with the native data using MOLREP [83] within the
HKL3000 software suite and BALBES [84] (R-factor of 42.2%,
correlation coefficient score of 0.634), as described previously.
Coordinates of MBL (PDB id 2YZ3) from P. aeruginosa, which
exhibits,33% identity with NDM-1 from K. pneumoniae, were used
as a search model. Further extensive model building was
performed manually in COOT [85], while crystallographic
maximum likelihood refinement with TLS groups [86] for two
protein chains were refined by PHENIX.refine [87]. The structure
of the two protein chains each containing residues 45–270 was
refined to final R and Rfree factors of 0.19 and 0.24, respectively.
The final model is characterized by a 0.007 A˚ rmsd from ideal
bond lengths. 97.8% of the residues occupy the most favored areas
of the Ramachandran plot according to the MOLPROBITY
validation results [88]. The 2.35 A˚ structure from the second
crystal with zinc acetate was determined by molecular replacement
using the first structure as a search model on HKL3000 and
refined using COOT and PHENIX.refine. The final refined
model of the two protein chains (residues of 44–270 and 45–270)
converged to the R and Rfree values of 0.21 and 0.28, respectively.
The two protein structures are very close in details (rmsd of 0.21 A˚
with 452 Ca atoms) except that the second structure contains an
acetate molecule in the active site. The structure was refined to a
final model after several rounds of COOT and PHENIX.refine
steps. Similarly, the third structure obtained from the co-
crystallization with aztreonam was also determined to 2.31 A˚ by
molecular replacement using the same search model (3RKJ). The
final refined structure includes one chain with residues 41–269 and
has an Rwork of 20.6% and Rfree of 27.0% with a good
stereochemistry. Although the antibiotic molecule was not present
in the structure, there were subtle changes found in the structure.
For the NDM-1 D36NY crystal obtained in the presence of zinc
chloride (mZnNDM-1 D36NY), the data were collected near the
zinc absorption peak energy (1.2825 A˚). However, zinc anomalous
diffraction signal was weak and structure could not be solved.
Instead, molecular replacement with the structure of chain A of
3Q6X as a search model yielded the structure using HKL3000.
The structure contained a single zinc bound NDM-1 D36NY in all
four monomers in the asymmetric unit. The subsequent number of
cycles of refinement by PHENIX.refine and COOT finalized the
structure with Rwork of 18.1% and Rfree of 23.6% with a good
stereochemistry. The final refinement statistics for all three
structures are presented in Table 1.
Steady State Kinetics
Steady state kinetic parameters were calculated for NDM-1 D38 b-
lactamase substrates by directly monitoring initial velocities as the
appearance or disappearance of the respective b-lactam antibiotic
chromophore over time; Nitrocefin (l= 486 nm, e= 20,500
M21 cm21), Imipenem (l= 298 nm, De= 9,035 M21 cm21), Te-
bipenem (l= 300 nm, De= 6,850 M21 cm21), Biapenem (l=
295 nm, De= 7,020 M21 cm21), Cefoxitin (l= 262 nm, De=
5,382 M21 cm21), Faropenem (l= 306 nm, De= 2,662 M21 cm21)
(Fig. S6). All experiments were performed in 10 mM HEPES
pH = 6.75, 250 mM NaCl, 100 mM ZnCl2. The final concentration
of NDM-1 was 10 nM. Reactions were performed in UV transparent
Costar 96 well plates and monitored with the Thermo Scientific
Multiskan Go plate reader. Initial velocities were fit to the Michaelis-
Menten Equation using KaleidaGraph 4.0.
PDB accession code
The atomic coordinates and structure factors have been
deposited in the PDB with accession code 3RKJ, 3RKK, 3SBL
and 3SFP.
Supporting Information
Figure S1 Sequence alignment of selected MBLs. Amino
acid sequence of K. pneumoniae NDM-1 was aligned with several
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MBLs (IMP-1 from Acinetobacter baumannii (gi110350569), IMP-4
from K. pneumoniae (gi|110350569), MBL from B. fragilis
(gi|22091056), MBL-2 from B. cereus ATCC 10876
(gi|229191531), VIM-1 protein from Enterobacter cloacae
(gi87158436), MBL VIM-11 from P. aeruginosa (gi|49035769),
VIM-2 from P. aeruginosa (gi|126571829)) using ClustalX. The ‘T’
denotes turns. The blue boxes denote residues with .0.7
similarity. The Figure was prepared using ESPript 2.2 (http://
espript.ibcp.fr/ESPript/ESPript).
(TIF)
Figure S2 Size exclusion chromatography of native
NDM-1 protein using a Superdex 200 GE Healthcare
16/60 column (blue circle). The separation was carried out at
22uC at a flow rate of 2.0 mL/min. The column was calibrated
with molecular weight standards (red circles) aprotinin (6.5 kDa),
ribonuclease (13.5 kDa), carbonic anhydrase (29 kDa), ovalbumin
(43 kDa), conalbumin (75 kDa), aldolase (158 kDa), catalase
(232 kDa), ferritin (440 kDa), and thyroglobulin (669 kDa). The
calibration curve of Kav versus log molecular weight was prepared
using the equation Kav = (Ve2Vo)/(Vt2Vo,), where Ve = elution
volume for the protein, Vo = column void volume, and Vt = total
bed volume.
(TIF)
Figure S3 Sequence alignment of structural homologs of
K. pneumoniae NDM-1. The top 250 structural homologs (Z-
score.10), as identified via the DALI server, were clustered (90%
sequence identity cut-off). The closest structural homologs are
MBLs, followed by class A, C, and D b-lactamases.
(TIF)
Figure S4 MBL loops. The representative structures from the
40 structure clusters (shown in Fig. S3), including NDM-1 (molA
of 3RKJ) were aligned based on the secondary structure. This
alignment reveals variation in the size of five loops contributing
amino acid side chains to the active site (labeled Active Site Loops,
ASL) in the NDM-1 structure compared to members of structural
clusters. NDM-1 shows the largest ASL1 and ASL4 loops in the
family.
(TIF)
Figure S5 K. pneumoniae NDM-1 is shown with antibi-
otics that serve as substrates for this MBL modeled into
the active site based on coordination of the b-lactam ring
to the proposed catalytic site. To highlight the wide range of
conformational states that the compounds occupy in the binding
pocket: Biapenem (B), Cefoxitin (C), Faropenem (D), Imipenem
(E), Nitrocefin (F) and Tebipenem (G) are shown grouped in A (see
kinetic data for these ligands in Fig. S6A–F). The b-lactam ring is
shown in black and wide stick representation. For reference, the
mobile ASL1 loop is shown in dark gray. Every molecule can be
posed within the active site without steric clashing; however, to
accomplish this, some unfavorable conformations are adopted.
(TIF)
Figure S6 Kinetic data for NDM-1 lactamase with
selected substrates. A. Kinetic data for NDM-1 D36NY with
Nitrocefin. B. Kinetic data for NDM-1 D36NY with Tebipenem.
C. Kinetic data for NDM-1 D36NY with Imipenem. D. Kinetic
data for NDM-1 D36NY with Biapenem. E. Kinetic data for
NDM-1 D36NY with Cefoxitin. F. Kinetic data for NDM-1
D36NY with Faropenem.
(TIF)
Acknowledgments
The authors thank all members of the Structural Biology Center at
Argonne National Laboratory for their help in conducting these
experiments.
Author Contributions
Conceived and designed the experiments: JS AJ. Performed the
experiments: YK CT JM RJ AB GB. Analyzed the data: YK AB GB JS
AJ. Contributed reagents/materials/analysis tools: RJ CT. Wrote the
paper: AJ JS YK GB.
References
1. Moellering Jr. RC (2010) NDM-1–a cause for worldwide concern. N Engl J Med
363: 2377–2379.
2. Cornaglia G, Giamarellou H, Rossolini GM (2011) Metallo-b-lactamases: a last
frontier for b-lactams? The Lancet infectious diseases 11: 381–393.
3. Llarrull LI, Testero Sa, Fisher JF, Mobashery S (2010) The future of the b-
lactams. Current opinion in microbiology 13: 551–557.
4. Drawz SM, Bonomo Ra (2010) Three decades of beta-lactamase inhibitors.
Clinical microbiology reviews 23: 160–201.
5. Nathwani D, Davey PG, Marwick CA (2010) MRSA: treating people with
infection. Clin Evid (Online) 2010.
6. Gillespie SH, Singh K (2011) XDR-TB, What is it; How is it Treated; and
Why is Therapeutic Failure so High? Recent Pat Antiinfect Drug Discov 6:
77–83.
7. Feldman C, Anderson R (2011) Bacteraemic pneumococcal pneumonia: current
therapeutic options. Drugs 71: 131–153.
8. Sarma JB, Bhattacharya PK, Kalita D, Rajbangshi M (2011) Multidrug-resistant
Enterobacteriaceae including metallo-b-lactamase producers are predominant
pathogens of healthcare-associated infections in an Indian teaching hospital.
Indian journal of medical microbiology 29: 22–27.
9. Chen Y, Zhou Z, Jiang Y, Yu Y (2011) Emergence of NDM-1-producing
Acinetobacter baumannii in China. The Journal of antimicrobial chemotherapy.
pp 1255–1259.
10. Yamamoto T, Takano T, Iwao Y, Hishinuma A (2011) Emergence of NDM-1-
positive capsulated Escherichia coli with high resistance to serum killing in
Japan. Journal of infection and chemotherapy : official journal of the Japan
Society of Chemotherapy 17: 435–439.
11. (CDC) CfDCaP (2010) Detection of Enterobacteriaceae isolates carrying
metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly
Rep 59: 750.
12. Marra A (2011) NDM-1: a local clone emerges with worldwide aspirations.
Future microbiology 6: 137–141.
13. Mulvey MR (2011) New Delhi Metallo-Beta-Lactamase in Klebsiella pneumo-
niae and Escherichia coli, Canada. Emerging Infectious Diseases 17: 1–10.
14. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, et al. (2010)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the
UK: a molecular, biological, and epidemiological study. The Lancet infectious
diseases 10: 597–602.
15. Bebrone C (2007) Metallo-beta-lactamases (classification, activity, genetic
organization, structure, zinc coordination) and their superfamily. Biochem
Pharmacol 74: 1686–1701.
16. Bush K, Jacoby Ga (2010) Updated functional classification of beta-lactamases.
Antimicrobial agents and chemotherapy 54: 969–976.
17. Walsh TR (2010) Emerging carbapenemases: a global perspective.
Int J Antimicrob Agents 36 Suppl 3: S8–14.
18. Harada S, Ishii Y, Yamaguchi K (2008) Extended-spectrum beta-lactamases:
implications for the clinical laboratory and therapy. The Korean journal of
laboratory medicine 28: 401–412.
19. Tamilselvi a, Mugesh G (2008) Zinc and antibiotic resistance: metallo-beta-
lactamases and their synthetic analogues. Journal of biological inorganic
chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
13: 1039–1053.
20. Jin W, Arakawa Y, Yasuzawa H, Taki T, Hashiguchi R, et al. (2004) Comparative
study of the inhibition of metallo-beta-lactamases (IMP-1 and VIM-2) by thiol
compounds that contain a hydrophobic group. Biol Pharm Bull 27: 851–856.
21. Siemann S, Clarke AJ, Viswanatha T, Dmitrienko GI (2003) Thiols as classical
and slow-binding inhibitors of IMP-1 and other binuclear metallo-beta-
lactamases. Biochemistry 42: 1673–1683.
22. Walsh TR, Weeks J, Livermore DM, Toleman Ma (2011) Dissemination of
NDM-1 positive bacteria in the New Delhi environment and its implications for
human health: an environmental point prevalence study. The Lancet infectious
diseases 11: 355–362.
23. Bush K (2010) Alarming beta-lactamase-mediated resistance in multidrug-
resistant Enterobacteriaceae. Curr Opin Microbiol 13: 558–564.
24. Carfi a, Pares S, Due´e E, Galleni M, Duez C, et al. (1995) The 3-D structure of a
zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein
fold. The EMBO journal 14: 4914–4921.
Structure and Function of NDM-1
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24621
25. Rasmussen BA, Yang Y, Jacobus N, Bush K (1994) Contribution of enzymatic
properties, cell permeability, and enzyme expression to microbiological activities
of beta-lactams in three Bacteroides fragilis isolates that harbor a metallo-beta-
lactamase gene. Antimicrob Agents Chemother 38: 2116–2120.
26. Garcı´a-Saez I, Hopkins J, Papamicael C, Franceschini N, Amicosante G, et al.
(2003) The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-
lactamase in complex with the inhibitor, D-captopril. The Journal of biological
chemistry 278: 23868–23873.
27. Queenan AM, Bush K (2007) Carbapenemases: the versatile beta-lactamases.
Clinical microbiology reviews 20: 440–458, table of contents.
28. Jean S-S, Hsueh P-R (2011) High burden of antimicrobial resistance in Asia.
International journal of antimicrobial agents 37: 291–295.
29. Bebrone C, Delbru¨ck H, Kupper MB, Schlo¨mer P, Willmann C, et al. (2009)
The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals
that the second inhibitory zinc ion binds in the histidine site. Antimicrobial
agents and chemotherapy 53: 4464–4471.
30. Walsh TR, Neville WA, Haran MH, Tolson D, Payne DJ, et al. (1998)
Nucleotide and amino acid sequences of the metallo-beta-lactamase, ImiS, from
Aeromonas veronii bv. sobria. Antimicrob Agents Chemother 42: 436–439.
31. Saavedra MJ, Peixe L, Sousa JC, Henriques I, Alves A, et al. (2003) Sfh-I, a
subclass B2 metallo-beta-lactamase from a Serratia fonticola environmental
isolate. Antimicrob Agents Chemother 47: 2330–2333.
32. McManus-Munoz S, Crowder MW (1999) Kinetic mechanism of metallo-beta-
lactamase L1 from Stenotrophomonas maltophilia. Biochemistry 38:
1547–1553.
33. Ullah JH, Walsh TR, Taylor Ia, Emery DC, Verma CS, et al. (1998) The crystal
structure of the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia
at 1.7 A resolution. Journal of molecular biology 284: 125–136.
34. Garcı´a-Sa´ez I, Mercuri PS, Papamicael C, Kahn R, Fre`re JM, et al. (2003)
Three-dimensional Structure of FEZ-1, a Monomeric Subclass B3 Metallo-b-
lactamase from Fluoribacter gormanii, in Native Form and in Complex with d-
Captopril. Journal of Molecular Biology 325: 651–660.
35. Mercuri PS, Garcı´a-Sa´ez I, De Vriendt K, Thamm I, Devreese B, et al. (2004)
Probing the specificity of the subclass B3 FEZ-1 metallo-beta-lactamase by site-
directed mutagenesis. The Journal of biological chemistry 279: 33630–33638.
36. Mora´n-Barrio J, Gonza´lez JM, Lisa MN, Costello AL, Peraro MD, et al. (2007)
The metallo-beta-lactamase GOB is a mono-Zn(II) enzyme with a novel active
site. The Journal of biological chemistry 282: 18286–18293.
37. Lisa M-n, Hemmingsen L, Vila AJ (2010) Catalytic Role of the Metal Ion in the
Metallo-beta-lactamase GOB. Journal of Biological Chemistry 285: 4570–4577.
38. Docquier J-D, Benvenuti M, Calderone V, Stoczko M, Menciassi N, et al. (2010)
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-
1: rational basis for substrate specificity and interaction with sulfonamides.
Antimicrobial agents and chemotherapy 54: 4343–4351.
39. Docquier J-d, Pantanella F, Giuliani F, Thaller MC, Amicosante G, et al. (2002)
CAU-1 , a Subclass B3 Metallo-beta-Lactamase of Low Substrate Affinity
Encoded by an Ortholog Present in the Caulobacter crescentus Chromosome.
Society 46: 1823–1830.
40. Rossolini GM, Condemi MA, Pantanella F, Docquier JD, Amicosante G, et al.
(2001) Metallo-beta-lactamase producers in environmental microbiota: new
molecular class B enzyme in Janthinobacterium lividum. Antimicrob Agents
Chemother 45: 837–844.
41. Ho PL, Lo WU, Yeung MK, Lin CH, Chow KH, et al. (2011) Complete
Sequencing of pNDM-HK Encoding NDM-1 Carbapenemase from a
Multidrug-Resistant Escherichia coli Strain Isolated in Hong Kong. PLoS
One 6: e17989.
42. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, et al. (2009)
Characterization of a New Metallo-beta-Lactamase Gene , bla NDM-1 , and a
Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in
Klebsiella pneumoniae Sequence Type 14 from India. Society 53: 5046–5054.
43. Ka¨ll L, Krogh A, Sonnhammer ELL (2004) A combined transmembrane
topology and signal peptide prediction method. Journal of molecular biology
338: 1027–1036.
44. Yu NY, Laird MR, Spencer C, Brinkman FSL (2011) PSORTdb–an expanded,
auto-updated, user-friendly protein subcellular localization database for Bacteria
and Archaea. Nucleic acids research 39: D241–244.
45. Jaroszewski L, Rychlewski L, Li Z, Li W, Godzik A (2005) FFAS03: a server for
profile–profile sequence alignments. Nucleic acids research 33: W284–288.
46. Concha NO, Janson Ca, Rowling P, Pearson S, Cheever Ca, et al. (2000) Crystal
structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa
and its complex with a mercaptocarboxylate inhibitor: binding determinants of a
potent, broad-spectrum inhibitor. Biochemistry 39: 4288–4298.
47. Garcia-Saez I, Docquier J-D, Rossolini GM, Dideberg O (2008) The three-
dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas
aeruginosa in its reduced and oxidised form. Journal of molecular biology 375:
604–611.
48. Lassaux P, Traore´ DaK, Loisel E, Favier A, Docquier J-D, et al. (2010)
Biochemical and Structural Characterization of the Subclass B1 Metallo-{beta}-
Lactamase VIM-4. Antimicrobial agents and chemotherapy 55: 1248–1255.
49. Zhang H, Hao Q (2011) Crystal structure of NDM-1 reveals a common {beta}-
lactam hydrolysis mechanism. The FASEB journal : official publication of the
Federation of American Societies for Experimental Biology. pp 1–9.
50. Holm L, Rosenstro¨m P (2010) Dali server: conservation mapping in 3D. Nucleic
acids research 38: W545–549.
51. Li W, Godzik A (2006) Cd-hit: a fast program for clustering and comparing large
sets of protein or nucleotide sequences. Bioinformatics (Oxford, England) 22:
1658–1659.
52. Laskowski RA, Watson JD, Thornton JM (2005) ProFunc: a server for predicting
protein function from 3D structure. Nucleic Acids Res 33: W89–93.
53. Concha NO, Rasmussen BA, Bush K, Herzberg O (1996) Crystal structure of
the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis.
Structure 4: 823–836.
54. Garau G, Bebrone C, Anne C, Galleni M, Fre`re J-M, et al. (2005) A metallo-
beta-lactamase enzyme in action: crystal structures of the monozinc carbape-
nemase CphA and its complex with biapenem. Journal of molecular biology 345:
785–795.
55. Yamaguchi Y, Jin W, Matsunaga K, Ikemizu S, Yamagata Y, et al. (2007)
Crystallographic investigation of the inhibition mode of a VIM-2 metallo-beta-
lactamase from Pseudomonas aeruginosa by a mercaptocarboxylate inhibitor.
Journal of medicinal chemistry 50: 6647–6653.
56. Fitzgerald PM, Wu JK, Toney JH (1998) Unanticipated inhibition of the
metallo-beta-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic
acid (MES): a crystallographic study at 1.85-A resolution. Biochemistry 37:
6791–6800.
57. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, et al. (2006) CASTp:
computed atlas of surface topography of proteins with structural and
topographical mapping of functionally annotated residues. Nucleic Acids Res
34: W116–118.
58. Zheng B, Tan S, Gao J, Han H, Liu J, et al. (2011) An unexpected similarity
between antibiotic-resistant NDM-1 and beta-lactamase II from Erythrobacter
litoralis. Protein & cell 2: 250–258.
59. Guo Y, Wang J, Niu G, Shui W, Sun Y, et al. (2011) A structural view of the
antibiotic degradation enzyme NDM-1 from a superbug. Protein & cell 2:
384–394.
60. Jacquin O, Balbeur D, Damblon C, Marchot P, De Pauw E, et al. (2009)
Positively cooperative binding of zinc ions to Bacillus cereus 569/H/9 beta-
lactamase II suggests that the binuclear enzyme is the only relevant form for
catalysis. Journal of molecular biology 392: 1278–1291.
61. Page MI, Badarau A (2008) The mechanisms of catalysis by metallo beta-
lactamases. Bioinorg Chem Appl: 576297.
62. Fabiane SM, Sohi MK, Wan T, Payne DJ, Bateson JH, et al. (1998) Crystal
structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A
resolution: binuclear active site with features of a mononuclear enzyme.
Biochemistry 37: 12404–12411.
63. Crowder MW, Spencer J, Vila AJ (2006) Metallo-beta-lactamases: novel
weaponry for antibiotic resistance in bacteria. Acc Chem Res 39: 721–728.
64. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR (2004)
Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new
subclass of metallo-beta-lactamase. Antimicrob Agents Chemother 48:
4654–4661.
65. Laraki N, Franceschini N, Rossolini GM, Santucci P, Meunier C, et al. (1999)
Biochemical characterization of the Pseudomonas aeruginosa 101/1477
metallo-beta-lactamase IMP-1 produced by Escherichia coli. Antimicrobial
agents and chemotherapy 43: 902–906.
66. Docquier J-D (2003) On functional and structural heterogeneity of VIM-type
metallo-beta-lactamases. Journal of Antimicrobial Chemotherapy 51: 257–266.
67. Tomatis PE, Fabiane SM, Simona F, Carloni P, Sutton BJ, et al. (2008) Adaptive
protein evolution grants organismal fitness by improving catalysis and flexibility.
Proceedings of the National Academy of Sciences of the United States of
America 105: 20605–20610.
68. Oelschlaeger P, Schmid RD, Pleiss J (2003) Insight into the mechanism of the
IMP-1 metallo–lactamase by molecular dynamics simulations. Protein Engi-
neering Design and Selection 16: 341–350.
69. Xu D, Guo H, Cui Q (2007) Antibiotic deactivation by a dizinc beta-lactamase:
mechanistic insights from QM/MM and DFT studies. J Am Chem Soc 129:
10814–10822.
70. Nocek BP, Gillner DM, Fan Y, Holz RC, Joachimiak A (2010) Structural basis
for catalysis by the mono- and dimetalated forms of the dapE-encoded N-
succinyl-L,L-diaminopimelic acid desuccinylase. Journal of molecular biology
397: 617–626.
71. Malanoski GJ, Collins L, Wennersten C, Moellering RC, Jr., Eliopoulos GM
(1993) In vitro activity of biapenem against clinical isolates of gram-positive and
gram-negative bacteria. Antimicrobial agents and chemotherapy 37: 2009–2016.
72. Clarke AM, Zemcov SJ (1993) Comparative in vitro activity of biapenem, a new
carbapenem antibiotic. European journal of clinical microbiology & infectious
diseases : official publication of the European Society of Clinical Microbiology
12: 377–384.
73. Peirano G, Schreckenberger PC, Pitout JD (2011) Characteristics of NDM-1-
Producing Escherichia coli Isolates That Belong to the Successful and Virulent
Clone ST131. Antimicrobial agents and chemotherapy 55: 2986–2988.
74. Kozawa O, Uematsu T, Matsuno H, Niwa M, Takiguchi Y, et al. (1998)
Pharmacokinetics and safety of a new parenteral carbapenem antibiotic,
biapenem (L-627), in elderly subjects. Antimicrobial agents and chemotherapy
42: 1433–1436.
75. Mori M, Hikida M, Nishihara T, Nasu T, Mitsuhashi S (1996) Comparative
stability of carbapenem and penem antibiotics to human recombinant
dehydropeptidase-I. The Journal of antimicrobial chemotherapy 37: 1034–1036.
Structure and Function of NDM-1
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24621
76. Aslanidis C, de Jong PJ (1990) Ligation-independent cloning of PCR products
(LIC-PCR). Nucleic Acids Res 18: 6069–6074.
77. Eschenfeldt WH, Lucy S, Millard CS, Joachimiak A, Mark ID (2009) A family of
LIC vectors for high-throughput cloning and purification of proteins. Methods
Mol Biol 498: 105–115.
78. Donnelly MI, Zhou M, Millard CS, Clancy S, Stols L, et al. (2006) An
expression vector tailored for large-scale, high-throughput purification of
recombinant proteins. Protein Expr Purif 47: 446–454.
79. Gill SC, von Hippel PH (1989) Calculation of protein extinction coefficients
from amino acid sequence data. Anal Biochem 182: 319–326.
80. Alkire RW, Molitsky M, Rotella FJ, Lazarski K, Joachimiak A (2010) A new
mini-beam device for protein crystallography. Nuclear Instruments and Methods
in Physics Research Section A: Accelerators, Spectrometers, Detectors and
Associated Equipment.
81. Rosenbaum G, Alkire RW, Evans G, Rotella FJ, Lazarski K, et al. (2006) The
Structural Biology Center 19ID undulator beamline: facility specifications and
protein crystallographic results. J Synchrotron Radiat 13: 30–45.
82. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M (2006) HKL-3000: the
integration of data reduction and structure solution–from diffraction images to
an initial model in minutes. Acta Crystallogr D Biol Crystallogr 62: 859–866.
83. Vagin A, Teplyakov A (2010) Molecular replacement with MOLREP. Acta
Crystallogr D Biol Crystallogr 66: 22–25.
84. Long F, Vagin AA, Young P, Murshudov GN (2008) BALBES: a molecular-
replacement pipeline. Acta Crystallogr D Biol Crystallogr 64: 125–132.
85. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
86. Winn MD, Isupov MN, Murshudov GN (2001) Use of TLS parameters to model
anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol
Crystallogr 57: 122–133.
87. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure
solution. Acta Crystallogr D Biol Crystallogr 66: 213–221.
88. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, et al.
(2010) MolProbity: all-atom structure validation for macromolecular crystallog-
raphy. Acta Crystallogr D Biol Crystallogr 66: 12–21.
Structure and Function of NDM-1
PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e24621
